| pubmed-article:15546135 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15546135 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:15546135 | lifeskim:mentions | umls-concept:C0239307 | lld:lifeskim |
| pubmed-article:15546135 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15546135 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:15546135 | lifeskim:mentions | umls-concept:C0027819 | lld:lifeskim |
| pubmed-article:15546135 | lifeskim:mentions | umls-concept:C0025241 | lld:lifeskim |
| pubmed-article:15546135 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:15546135 | lifeskim:mentions | umls-concept:C0444956 | lld:lifeskim |
| pubmed-article:15546135 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:15546135 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:15546135 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15546135 | pubmed:dateCreated | 2005-2-21 | lld:pubmed |
| pubmed-article:15546135 | pubmed:abstractText | High dose myeloablative chemotherapy ("megatherapy"), with haematopoietic stem cell support, is now widely used to consolidate response to induction chemotherapy in patients with advanced neuroblastoma. | lld:pubmed |
| pubmed-article:15546135 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15546135 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15546135 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15546135 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15546135 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15546135 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15546135 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15546135 | pubmed:issn | 1545-5009 | lld:pubmed |
| pubmed-article:15546135 | pubmed:author | pubmed-author:JonesDavid... | lld:pubmed |
| pubmed-article:15546135 | pubmed:author | pubmed-author:de KrakerJanJ | lld:pubmed |
| pubmed-article:15546135 | pubmed:author | pubmed-author:PritchardJonJ | lld:pubmed |
| pubmed-article:15546135 | pubmed:author | pubmed-author:CotterillSimo... | lld:pubmed |
| pubmed-article:15546135 | pubmed:author | pubmed-author:ImesonJohnJ | lld:pubmed |
| pubmed-article:15546135 | pubmed:author | pubmed-author:GermondShirle... | lld:pubmed |
| pubmed-article:15546135 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15546135 | pubmed:volume | 44 | lld:pubmed |
| pubmed-article:15546135 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15546135 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15546135 | pubmed:pagination | 348-57 | lld:pubmed |
| pubmed-article:15546135 | pubmed:dateRevised | 2009-1-12 | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:meshHeading | pubmed-meshheading:15546135... | lld:pubmed |
| pubmed-article:15546135 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15546135 | pubmed:articleTitle | High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. | lld:pubmed |
| pubmed-article:15546135 | pubmed:affiliation | Department of Surgery, Institute of Child Health, London, United Kingdom. | lld:pubmed |
| pubmed-article:15546135 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15546135 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15546135 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15546135 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15546135 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15546135 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15546135 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15546135 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15546135 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15546135 | lld:pubmed |
